| Latest Breaking News from Modern Healthcare
| Gilead paying up to $1.2B for Nimbus unit, drug, technology | | Monday, April 04, 2016 2:09 PM | |
| | Biologic drugmaker Gilead Sciences is buying a subsidiary of Nimbus Therapeutics and its experimental medicine for an increasingly prevalent metabolic disorder that causes dangerous fat buildup in the liver. |
| Blog: Yelp provides untapped insight into patient experience | | Monday, April 04, 2016 11:49 AM | |
| | Excessively pricey bills, long waits for staff, rude doctors and difficulties setting up appointments drove people to rant about their hospitals on Yelp. But these factors are not included on surveys sent to patients discharged from U.S. hospitals. |
|